Detection, Treatment, and Prevention of Clostridium difficile Infection

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 6, 2012, Pages 581-592

  McCollum, David L ^a   Rodriguez, J Martin ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Antimicrobial Associated Diarrhea; Clostridium difficile Infection; Fidaxomicin; Metronidazole; Vancomycin

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BACTERIAL VACCINE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE VACCINE; CLOSTRIDIUM TOXIN; FIDAXOMICIN; GASTROINTESTINAL AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LAXATIVE; MACROLIDE; METRONIDAZOLE; MONOCLONAL ANTIBODY; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; CANCER CHEMOTHERAPY; CEREBELLUM DISEASE; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL ENDOSCOPY; HAZARD RATIO; HEALTH CARE COST; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; IRRITABLE COLON; LABORATORY TEST; LONG TERM CARE; MORBIDITY; MORTALITY; NEUROPATHY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; REACTIVE ARTHRITIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT INDICATION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; HUMANS;

EID: 84861331778     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.03.008     Document Type: Review

References (178)

1. Hall I. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935, 390-402.
2. Bartlett J.G. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S4-S11.
3. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983, 2:1043-1046.
4. Wenisch C., Parschalk B., Hasenhündl M., et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22:813-818.
5. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
6. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
7. Hyland M., Ofner-Agostini M., Miller M., et al. N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD prevalence surveillance project. Can J Infect Dis 2001, 12:81-88.
8. Miller M.A., Hyland M., Ofner-Agostini M., et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002, 23:137-140.
9. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerging Infect Dis Jun 2008, 14:929-931.
10. Zilberberg M.D. Clostridium difficile-related hospitalizations among US adults, 2006. Emerging Infect Dis 2009, 15:122-124.
11. Severe Clostridium difficile-associated disease in populations previously at low risk: four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1201-1205. Centers for Disease Control and Prevention.
12. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
13. McDonald L.C., Coignard B., Dubberke E., et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28:140-145.
14. Freeman J., Bauer M.P., Baines S.D., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
15. Elixhauser A.A., Jhung M. Clostridium difficile-associated disease in U.S in hospitals, 1993-2005: HCUP statistical brief #50 2008, Agency for Healthcare Research and Quality, Rockville, MD.
16. Miller B.A., Chen L.F., Sexton D.J., et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011, 32:387-390.
17. Kuntz J.L., Chrischilles E.A., Pendergast J.F., et al. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis 2011, 11:194.
18. Khanna S., Pardi D.S., Aronson S.L., et al. The Epidemiology of Community-Acquired Clostridium difficile Infection: a population-based study. Am J Gastroenterol 2012, 107:89-95.
19. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
20. Dubberke E.R., Wertheimer A.I. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:57-66.
21. McGlone S.M., Bailey R.R., Zimmer S.M., et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012, 18:282-289.
22. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989, 320:204-210.
23. Clabots C.R., Johnson S., Olson M.M., et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992, 166:561-567.
24. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011, 365:1693-1703.
25. Kim J.H., Toy D., Muder R.R. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol 2011, 32:656-660.
26. Pépin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
27. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 19962003. Emerging Infect Dis 2006, 12:409-415.
28. Karen C.C., John G.B. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011, 65:501-521.
29. Manges A.R., Labbe A., Loo V.G., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 2010, 202:1877-1884.
30. Pépin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
31. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
32. McFarland L.V., Clarridge J.E., Beneda H.W., et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007, 45:1141-1151.
33. Hensgens M.P., Goorhuis A., van Kinschot C.M., et al. Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 2011, 30:587-593.
34. Weiss K. Clostridium difficile and fluoroquinolones: is there a link?. Int J Antimicrob Agents 2009, 33(Suppl 1):S29-S32.
35. Blondeau J.M. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?. J Antimicrob Chemother 2009, 63:238-242.
36. Adams D.A., Riggs M.M., Donskey C.J. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007, 51:2674-2678.
37. Kallen A.J., Thompson A., Ristaino P., et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009, 30:264-272.
38. Davey P., Brown E., Fenelon L., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005, 4. CD003543.
39. George P., Morris A.M. Pro/con debate: should antimicrobial stewardship programs be adopted universally in the intensive care unit?. Crit Care 2010, 14:205.
40. Biller P., Shank B., Lind L., et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007, 28:198-201.
41. Dhalla I.A., Mamdani M.M., Simor A.E., et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?. Antimicrob Agents Chemother 2006, 50:3216-3219.
42. Hensgens M.P., Goorhuis A., Dekkers O.M., et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012, 67:742-748.
43. Stevens V., Dumyati G., Fine L.S., et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
44. Carignan A., Allard C., Pepin J., et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008, 46:1838-1843.
45. Polgreen P.M., Yang M., Bohnett L.C., et al. A time-series analysis of Clostridium difficile and its seasonal association with influenza. Infect Control Hosp Epidemiol 2010, 31:382-387.
46. Bavishi C., Dupont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34:1269-1281.
47. Jump R.L., Pultz M.J., Donskey C.J. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?. Antimicrob Agents Chemother 2007, 51:2883-2887.
48. Garey K.W., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008, 70:298-304.
49. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
50. Cadle R.M., Mansouri M.D., Logan N., et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007, 64:2359-2363.
51. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170:784-790.
52. Collini P.J., Bauer M., Kuijper E., et al. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect 2012, 64:131-147.
53. Rodemann J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
54. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
55. Eddi R., Malik M.N., Shakov R., et al. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton) 2010, 15:471-475.
56. Ananthakrishnan A.N., McGinley E.L., Saeian K., et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:976-983.
57. Raines D.L., Lopez F.A. Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients. Curr Gastroenterol Rep 2011, 13:344-350.
58. Riddle D.J., Dubberke E.R. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008, 13:592-600.
59. Bliss D.Z., Johnson S., Savik K., et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998, 129:1012-1019.
60. Das R., Feuerstadt P., Brandt L.J. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol 2010, 105:2040-2049.
61. Leffler D.A., Lamont J.T. Editorial: not so nosocomial anymore-the growing threat of community-acquired Clostridium difficile. Am J Gastroenterol 2012, 107:96-98.
62. Khanna S., Pardi D.S., Aronson S.L., et al. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 2012, 35:613-618.
63. Gould L.H., Limbago B. Clostridium difficile in food and domestic animals: a new foodborne pathogen?. Clin Infect Dis 2010, 51:577-582.
64. Bouttier S., Barc M.C., Felix B., et al. Clostridium difficile in ground meat, France. Emerging Infect Dis 2010, 16:733-735.
65. Steele J., Chen K., Sun X., et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 2012, 205:384-391.
66. Kuehne S.A., Cartman S.T., Heap J.T., et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
67. Pituch H., van den Braak N., van Leeuwen W., et al. Clonal dissemination of a toxin-A-negative/toxin-B-positive Clostridium difficile strain from patients with antibiotic-associated diarrhea in Poland. Clin Microbiol Infect 2001, 7:442-446.
68. Cohen S.H., Tang Y.J., Hansen B., et al. Isolation of a toxin B-deficient mutant strain of Clostridium difficile in a case of recurrent C. difficile-associated diarrhea. Clin Infect Dis 1998, 26:410-412.
69. Jangi S., Lamont J.T. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 2010, 51:2-7.
70. Riggs M.M., Sethi A.K., Zabarsky T.F., et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992-998.
71. Muto C.A. Asymptomatic Clostridium difficile colonization: is this the tip of another iceberg?. Clin Infect Dis 2007, 45:999-1000.
72. Leav B.A., Blair B., Leney M., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28:965-969.
73. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011, 60:1070-1079.
74. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342:390-397.
75. Warny M., Vaerman J.P., Avesani V., et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994, 62:384-389.
76. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
77. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
78. Kotloff K.L., Wasserman S.S., Losonsky G.A., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001, 69:988-995.
79. Högenauer C., Langner C., Beubler E., et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006, 355:2418-2426.
80. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S12-S18.
81. Bulusu M., Narayan S., Shetler K., et al. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000, 95:3137-3141.
82. Wanahita A., Goldsmith E.A., Musher D.M. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002, 34:1585-1592.
83. Wanahita A., Goldsmith E.A., Marino B.J., et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003, 115:543-546.
84. Garey K.W., Dao-Tran T.K., Jiang Z.D., et al. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect 2008, 70:142-147.
85. Kyne L., Sougioultzis S., McFarland L.V., et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002, 23:653-659.
86. Dubberke E.R., Yan Y., Reske K.A., et al. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol 2011, 32:360-366.
87. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
88. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
89. Wenisch J.M., Schmid D., Kuo H.W., et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis 2011, Dec 31 [Epub ahead of print].
90. Longo W.E., Mazuski J.E., Virgo K.S., et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004, 47:1620-1626.
91. Lamontagne F., Labbé A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007, 245:267-272.
92. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235:363-372.
93. Sailhamer E.A., Carson K., Chang Y., et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009, 144:433-439. discussion 439-440.
94. Karas J.A., Enoch D.A., Aliyu S.H. A review of mortality due to Clostridium difficile infection. J Infect 2010, 61:1-8.
95. Kelly C.P., LaMont J.T. Clostridium difficile: more difficult than ever. N Engl J Med 2008, 359:1932-1940.
96. Kamboj M., Khosa P., Kaltsas A., et al. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis 2011, 53:1003-1006.
97. Shakov R., Salazar R.S., Kagunye S.K., et al. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Contr 2011, 39:194-198.
98. Feldman R.J., Kallich M., Weinstein M.P. Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Clin Infect Dis 1995, 20:1560-1562.
99. Wolf L.E., Gorbach S.L., Granowitz E.V. Extraintestinal Clostridium difficile: 10 years' experience at a tertiary-care hospital. Mayo Clin Proc 1998, 73:943-947.
100. Deptuła A., Kruszyńska E., Mikucka A., et al. Toxin A-producing Clostridium difficile as an aetiological factor of post-traumatic wound infection. J Med Microbiol 2009, 58:963-964.
101. Birnbaum J., Bartlett J.G., Gelber A.C. Clostridium difficile: an under-recognized cause of reactive arthritis?. Clin Rheumatol 2008, 27:253-255.
102. Sethi S., Garey K.W., Arora V., et al. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infection. J Hosp Infect 2011, 77:172-173.
103. Kufelnicka A.M., Kirn T.J. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011, 52:1451-1457.
104. Aichinger E., Schleck C.D., Harmsen W.S., et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008, 46:3795-3797.
105. Deshpande A., Pasupuleti V., Patel P., et al. Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol 2011, 9:665-669.
106. Eastwood K., Else P., Charlett A., et al. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009, 47:3211-3217.
107. Deshpande A., Pasupuleti V., Rolston D.D., et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis 2011, 53:e81-e90.
108. Tenover F.C., Novak-Weekley S., Woods C.W., et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol 2010, 48:3719-3724.
109. Burkart N.E., Kwaan M.R., Shepela C., et al. Indications and relative utility of lower endoscopy in the management of Clostridium difficile infection. Gastroenterol Res Pract 2011, 2011:626582. Epub 2011 Oct 17.
110. Gerding D.N., Olson M.M., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med 1986, 146:95-100.
111. Bartlett J.G. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002, 346:334-339.
112. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997, 92:739-750.
113. Morrison R.H., Hall N.S., Said M., et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011, 53:1173-1178.
114. Koo H.L., Koo D.C., Musher D.M., et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009, 48:598-605.
115. Bartlett J.G. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 2010, 1213:62-69.
116. Gonzales M., Pepin J., Frost E.H., et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010, 10:363.
117. Chihara S., Shimizu R., Furukata S., et al. Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis. Scand J Infect Dis 2011, 43:149-150.
118. Aradhyula S., Manian F.A., Hafidh S.A., et al. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2006, 99:518-520.
119. Matzke G.R., Halstenson C.E., Olson P.L., et al. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987, 9:422-425.
120. Pépin J., Valiquette L., Gagnon S., et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007, 102:2781-2788.
121. Al-Nassir W.N., Sethi A.K., Li Y., et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52:2403-2406.
122. Sethi A.K., Al-Nassir W.N., Nerandzic M.M., et al. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2009, 30:13-17.
123. Pruksananonda P., Powell K.R. Multiple relapses of Clostridium difficile-associated diarrhea responding to an extended course of cholestyramine. Pediatr Infect Dis J 1989, 8:175-178.
124. Kunimoto D., Thomson A.B. Recurrent Clostridium difficile-associated colitis responding to cholestyramine. Digestion 1986, 33:225-228.
125. Moncino M.D., Falletta J.M. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient: successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol 1992, 14:361-364.
126. Mogg G.A., George R.H., Youngs D., et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 1982, 69:137-139.
127. Kurtz C.B., Cannon E.P., Brezzani A., et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001, 45:2340-2347.
128. Taylor N.S., Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980, 141:92-97.
129. Drekonja D.M., Butler M., Macdonald R., et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011, 155:839-847.
130. Apisarnthanarak A., Razavi B., Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002, 35:690-696.
131. Butala P., Divino C.M. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg 2010, 200:131-135.
132. Neal M.D., Alverdy J.C., Hall D.E., et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011, 254:423-427. discussion 427-429.
133. Freiler J.F., Durning S.J., Ender P.T. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis 2001, 33:1429-1431.
134. Bobo L.D., Dubberke E.R., Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011, 140:1643-1653.
135. Juang P., Skledar S.J., Zgheib N.K., et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Contr 2007, 35:131-137.
136. McPherson S., Rees C.J., Ellis R., et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006, 49:640-645.
137. Herpers B.L., Vlaminckx B., Burkhardt O., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009, 48:1732-1735.
138. You D.M., Franzos M.A., Holman R.P. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med 2008, 148:632-633.
139. Tannock G.W., Munro K., Taylor C., et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010, 156:3354-3359.
140. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
141. Mullane K.M., Miller M.A., Weiss K., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447.
142. Koo H.L., Garey K.W., Dupont H.L. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs 2010, 19:825-836.
143. Musher D.M., Logan N., Hamill R.J., et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006, 43:421-427.
144. Musher D.M., Logan N., Bressler A.M., et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009, 48:e41-e46.
145. Musher D.M., Logan N., Mehendiratta V., et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007, 59:705-710.
146. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44:846-848.
147. Johnson S., Schriever C., Patel U., et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15:290-291.
148. Garey K.W., Ghantoji S.S., Shah D.N., et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011, 66:2850-2855.
149. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53:994-1002.
150. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
151. Rubin T.A., Gessert C.E., Aas J. Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc 2009, 57:2386.
152. Phase II/III randomized controlled trial of oral vancomycin followed by fecal transplantation versus tapering oral vancomycin for recurrent Clostridium difficile infection (CDI) University Health Network, Accessed January 11, 2012. http://clinicaltrials.gov/show/NCT01226992%20NLM%20Identifier:%20NCT01226992.
153. Ho N., Prasad V. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. J Clin Gastroenterol 2011, 45:379-380.
154. McKenna M. Swapping germs. Sci Am 2011, 305:34. 36.
155. Silverman M.S., Davis I., Pillai D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010, 8:471-473.
156. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
157. Pillai A., Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008, 1. CD004611.
158. Dendukuri N., Costa V., McGregor M., et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005, 173:167-170.
159. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010, 16:2202-2222.
160. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
161. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
162. Muñoz P., Bouza E., Cuenca-Estrella M., et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005, 40:1625-1634.
163. Rautio M., Jousimies-Somer H., Kauma H., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999, 28:1159-1160.
164. Cassone M., Serra P., Mondello F., et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003, 41:5340-5343.
165. Enache-Angoulvant A., Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005, 41:1559-1568.
166. Kaslow D.C., Shiver J.W. Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development. Annu Rev Med 2011, 62:201-215.
167. US FDA grants fast-track designation to Sanofi Pasteur's investigational Clostridium difficile vaccine. Clin Infect Dis 2011, 52:i-ii.
168. Lee B.Y., Popovich M.J., Tian Y., et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010, 28:5245-5253.
169. Berild D., Smaabrekke L., Halvorsen D.S., et al. Clostridium difficile infections related to antibiotic use and infection control facilities in two university hospitals. J Hosp Infect 2003, 54:202-206.
170. Best E.L., Fawley W.N., Parnell P., et al. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 2010, 50:1450-1457.
171. Cartmill T.D., Panigrahi H., Worsley M.A., et al. Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect 1994, 27:1-15.
172. Kaatz G.W., Gitlin S.D., Schaberg D.R., et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988, 127:1289-1294.
173. Hacek D.M., Ogle A.M., Fisher A., et al. Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am J Infect Contr 2010, 38:350-353.
174. Bartlett J.G. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011, 53(Suppl 1):S4-S7.
175. Pear S.M., Williamson T.H., Bettin K.M., et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994, 120:272-277.
176. Talpaert M.J., Gopal Rao G., Cooper B.S., et al. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011, 66:2168-2174.
177. Muto C.A., Blank M.K., Marsh J.W., et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 2007, 45:1266-1273.
178. Abbett S.K., Yokoe D.S., Lipsitz S.R., et al. Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:1062-1069.